551 related articles for article (PubMed ID: 27853808)
1. RE-COVERY DVT/PE: Rationale and design of a prospective observational study of acute venous thromboembolism with a focus on dabigatran etexilate.
Ageno W; Casella IB; Han CK; Raskob GE; Schellong S; Schulman S; Singer DE; Kimura K; Tang W; Desch M; Goldhaber SZ
Thromb Haemost; 2017 Jan; 117(2):415-421. PubMed ID: 27853808
[TBL] [Abstract][Full Text] [Related]
2. The cost-utility of dabigatran etexilate compared with warfarin in treatment and extended anticoagulation of acute VTE in the UK.
Jugrin AV; Ustyugova A; Urbich M; Lamotte M; Sunderland T
Thromb Haemost; 2015 Oct; 114(4):778-92. PubMed ID: 26272227
[TBL] [Abstract][Full Text] [Related]
3. Acute phase treatment of VTE: Anticoagulation, including non-vitamin K antagonist oral anticoagulants.
Hillis C; Crowther MA
Thromb Haemost; 2015 Jun; 113(6):1193-202. PubMed ID: 25948149
[TBL] [Abstract][Full Text] [Related]
4. Indirect comparison and cost-utility of dabigatran etexilate and rivaroxaban in the treatment and extended anticoagulation of venous thromboembolism in a UK setting.
Jugrin AV; Hösel V; Ustyugova A; De Francesco M; Lamotte M; Sunderland T
J Med Econ; 2016; 19(1):1-10. PubMed ID: 26390231
[TBL] [Abstract][Full Text] [Related]
5. Profile of Patients Diagnosed With Acute Venous Thromboembolism in Routine Clinical Practice: The RE-COVERY DVT/PE™ Study.
Goldhaber SZ; Ageno W; Casella IB; Chee KH; Schellong S; Singer DE; Desch M; Reilly PA; Donado E; Tang W; Voccia I; Schulman S
Am J Med; 2020 Aug; 133(8):936-945. PubMed ID: 32325043
[TBL] [Abstract][Full Text] [Related]
6. Phase IIa study of dabigatran etexilate in children with venous thrombosis: pharmacokinetics, safety, and tolerability.
Halton JML; Albisetti M; Biss B; Bomgaars L; Brueckmann M; Gropper S; Harper R; Huang F; Luciani M; Maas H; Tartakovsky I; Mitchell LG
J Thromb Haemost; 2017 Nov; 15(11):2147-2157. PubMed ID: 28921890
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness of Dabigatran Compared to Vitamin-K Antagonists for the Treatment of Deep Venous Thrombosis in the Netherlands Using Real-World Data.
van Leent MW; Stevanović J; Jansman FG; Beinema MJ; Brouwers JR; Postma MJ
PLoS One; 2015; 10(8):e0135054. PubMed ID: 26241880
[TBL] [Abstract][Full Text] [Related]
8. Safety and effectiveness of dabigatran in routine clinical practice: the RE-COVERY DVT/PE study.
Goldhaber SZ; Ageno W; Casella IB; Chee KH; Schellong S; Singer DE; Voccia I; Tang W; Schulman S
J Thromb Thrombolysis; 2022 Feb; 53(2):399-409. PubMed ID: 34453675
[TBL] [Abstract][Full Text] [Related]
9. Anticoagulation strategies for venous thromboembolism: moving towards a personalised approach.
Black SA; Cohen AT
Thromb Haemost; 2015 Oct; 114(4):660-9. PubMed ID: 26084864
[TBL] [Abstract][Full Text] [Related]
10. Differential benefit risk assessment of DOACs in the treatment of venous thromboembolism: focus on dabigatran.
Leung TS; Law EH
Drug Des Devel Ther; 2015; 9():3557-69. PubMed ID: 26185422
[TBL] [Abstract][Full Text] [Related]
11. Direct oral anticoagulants in the treatment of venous thromboembolism, with a focus on patients with pulmonary embolism: an evidence-based review.
Gómez-Outes A; Suárez-Gea ML; Lecumberri R; Terleira-Fernández AI; Vargas-Castrillón E
Vasc Health Risk Manag; 2014; 10():627-39. PubMed ID: 25404858
[TBL] [Abstract][Full Text] [Related]
12. Direct oral anticoagulants and venous thromboembolism.
Franchini M; Mannucci PM
Eur Respir Rev; 2016 Sep; 25(141):295-302. PubMed ID: 27581829
[TBL] [Abstract][Full Text] [Related]
13. Current and emerging strategies in the management of venous thromboembolism: benefit-risk assessment of dabigatran.
Fanola CL
Vasc Health Risk Manag; 2015; 11():271-82. PubMed ID: 26064057
[TBL] [Abstract][Full Text] [Related]
14. Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer.
Schulman S; Goldhaber SZ; Kearon C; Kakkar AK; Schellong S; Eriksson H; Hantel S; Feuring M; Kreuzer J
Thromb Haemost; 2015 Jul; 114(1):150-7. PubMed ID: 25739680
[TBL] [Abstract][Full Text] [Related]
15. Dabigatran versus Warfarin for Acute Venous Thromboembolism in Elderly or Impaired Renal Function Patients: Pooled Analysis of RE-COVER and RE-COVER II.
Goldhaber SZ; Schulman S; Eriksson H; Feuring M; Fraessdorf M; Kreuzer J; Schüler E; Schellong S; Kakkar A
Thromb Haemost; 2017 Nov; 117(11):2045-2052. PubMed ID: 29202209
[TBL] [Abstract][Full Text] [Related]
16. Treatment of patients with acute deep vein thrombosis and/or pulmonary embolism: efficacy and safety of non-VKA oral anticoagulants in selected populations.
Prandoni P
Thromb Res; 2014 Aug; 134(2):227-33. PubMed ID: 24875390
[TBL] [Abstract][Full Text] [Related]
17. Safety and Efficacy of Dabigatran Etexilate vs Dose-Adjusted Warfarin in Patients With Cerebral Venous Thrombosis: A Randomized Clinical Trial.
Ferro JM; Coutinho JM; Dentali F; Kobayashi A; Alasheev A; Canhão P; Karpov D; Nagel S; Posthuma L; Roriz JM; Caria J; Frässdorf M; Huisman H; Reilly P; Diener HC;
JAMA Neurol; 2019 Dec; 76(12):1457-1465. PubMed ID: 31479105
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism in the presence of thrombophilia: Findings from RE-COVER®, RE-COVER™ II, and RE-MEDY™.
Goldhaber SZ; Eriksson H; Kakkar A; Schellong S; Feuring M; Fraessdorf M; Kreuzer J; Schueler E; Schulman S
Vasc Med; 2016 Dec; 21(6):506-514. PubMed ID: 27807306
[TBL] [Abstract][Full Text] [Related]
19. Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II.
Goldhaber SZ; Schellong S; Kakkar A; Eriksson H; Feuring M; Kreuzer J; Fraessdorf M; Schulman S
Thromb Haemost; 2016 Sep; 116(4):714-21. PubMed ID: 27411591
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
Coleman CI; Bunz TJ; Turpie AGG
Thromb Haemost; 2017 Oct; 117(10):1841-1847. PubMed ID: 28640322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
